N-琥珀酰亚胺基3-(三甲基锡烷基)苯甲酸酯 | 122856-01-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-琥珀酰亚胺基3-(三甲基锡烷基)苯甲酸酯
• 英文名称: N-succinimidyl 3-trimethylstannylbenzoate
• 英文别名: N-succinimidyl meta-trimethylstannylbenzoate；MeSTB；3-trimethylstannyl-benzoic acid 2,5-dioxo-pyrrolidin-1-yl ester；N-Succinimidyl 3-(trimethylstannyl)benzoate；(2,5-dioxopyrrolidin-1-yl) 3-trimethylstannylbenzoate
• CAS: 122856-01-3
• 化学式: C₁₄H₁₇NO₄Sn
• 分子量: 382.003
• InChiKey: FAWLNYODPPEZHK-UHFFFAOYSA-N

物化性质

• 溶解度：
  氯仿（微溶）、乙酸乙酯（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  1.45
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  63.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-琥珀酰亚胺基3-(三甲基锡烷基)苯甲酸酯 在 sodium hydroxide 、 N-氯代丁二酰亚胺 、 sodium iodide 、 溶剂黄146 作用下， 以 甲醇 、 水 为溶剂， 反应 0.25h， 生成 N-succinimidyl 3-[125I]iodobenzoate
  参考文献：
  名称：

  Feasibility of the radioastatination of a monoclonal antibody with astatine-211 purified by wet extraction

  摘要：

  Astatine-211是一种非常有前景的α粒子发射体，可用于靶向放射治疗，通常通过高温蒸馏获得。不过，也有文献描述了液-液萃取程序（湿法萃取）。本研究的目的是开发并优化N-羟基琥珀酰亚胺基-间三甲基锡苯甲酸酯（MeSTB）的标记，在氧化剂N-氯代琥珀酰亚胺（NCS）的作用下，用二异丙醚（DIPE）萃取astatine-211。研究了最终体积、孵育时间和NCS量对放射性标记产率的影响。在120微升二异丙醚中，用20毫摩尔MeSTB、100毫摩尔NCS，经过15分钟，获得了N-羟基琥珀酰亚胺基-间[211At]astatobenzoate酯（SAB）的最佳产率（85-90%）。然后，用astatine-211标记的活性酯对单克隆抗体（mAb）进行放射性标记。标记产率为20-25%，放射化学纯度为97-99%。这些结果表明，mAbs可以用湿法萃取获得的astatine-211进行有效标记，这种全自动技术可能证明是干馏法的一种有用替代

  DOI：

  10.1002/jlcr.1543
• 作为产物：
  描述：

  N-羟基丁二酰亚胺 、 3-三甲基锡烷基苯甲酸 在 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-琥珀酰亚胺基3-(三甲基锡烷基)苯甲酸酯
  参考文献：
  名称：

  [EN] RADIOIODINATION METHOD
  [FR] PROCÉDÉ DE MARQUAGE À L'IODE RADIOACTIF

  摘要：

  本发明提供了一种合成放射碘化合物的方法，该方法优于先前的方法。在间接放射碘化反应中使用肼或氨氧代替一级胺有利于加快反应速度，从而减少反应时间并增加产量。此外，如果分子中存在要进行放射碘化的一级胺，例如肽的N-末端或赖氨酸残基，则在肼或氨氧处的反应将得到极大的偏好。

  公开号：

  WO2010086398A1

文献信息

• HALOGENATED BIOTIN-MODIFIED DIMER AND USE THEREOF
  申请人：The University of Tokyo

  公开号：US20210214376A1

  公开（公告）日：2021-07-15

  An object of the present invention is to provide a halogenated biotin-modified dimer, which is capable of imaging diagnosis or treatment by labeling with a halogen, a biotin-modified dimer having a high affinity for a mutant streptavidin with a low affinity for natural biotin. The present invention provides a compound represented by the following formula (1) or a salt thereof: wherein the meaning of each symbol is the same as that described in the specification.

  本发明的目的是提供一种卤代生物素修饰二聚体，该二聚体能够通过标记卤素进行成像诊断或治疗，并具有高亲和力的突变链霉亲和素和低亲和力的天然生物素。本发明提供了以下式（1）所表示的化合物或其盐：其中每个符号的含义与说明书中描述的相同。
• RADIOIODINATION METHOD
  申请人：Avory Michelle

  公开号：US20110280803A1

  公开（公告）日：2011-11-17

  The present invention provides a method for the synthesis of radioiodinated compounds which is advantageous over prior art methods. Using a hydrazine or an aminoxy in place of a primary amine for indirect radioiodination facilitates a much quicker reaction thus reducing reaction time and increasing the yield. In addition, where there are primary amines in the molecule to be radioiodinated, such as the N-terminus of a peptide or lysine residues, reaction at the hydrazine or aminoxy is greatly favoured.

  本发明提供了一种合成放射性碘化合物的方法，相比先前的方法具有优势。使用肼或氨氧基代替一级胺来进行间接放射性碘化反应，可以加快反应速度，从而减少反应时间并增加产量。此外，如果分子中存在一级胺，例如肽的N-末端或赖氨酸残基，则在肼或氨氧基处进行反应的倾向性大大增加。
• Towards to hENT1-nucleoside transporter selective imaging agents. Synthesis and in vitro evaluation of the radiolabeled SAENTA analogues
  作者：Boris D. Zlatopolskiy、Agnieszka Morgenroth、Elizaveta A. Urusova、Cornelia Dinger、Thomas Kull、Manuela Pape、Gerhard Glatting、Sven N. Reske

  DOI：10.1016/j.bmcl.2009.07.017

  日期：2009.9

  Three new potential hENT(1) inhibitors suitable for labeling with PET/SPECT radioisotopes were prepared from an advanced intermediate 4. They were tested for their capability to inhibit binding of SAENTA-fluorescein to HL60 leukemia cells in flow cytometry assay and SAENTA-I (5) was determined to be the most active compound. I-131-5 showed high hENT(1)-specific binding (up to 54% ID) to 6 from 7 tested tumor cell lines and was chosen for further in vivo study. (C) 2009 Elsevier Ltd. All rights reserved.
• Preliminary Evaluation of Astatine-211-Labeled Bombesin Derivatives for Targeted Alpha Therapy
  作者：Miho Aoki、Songji Zhao、Kazuhiro Takahashi、Kohshin Washiyama、Naoyuki Ukon、Chengbo Tan、Saki Shimoyama、Ken-ichi Nishijima、Kazuma Ogawa

  DOI：10.1248/cpb.c20-00077

  日期：2020.6.1

  There are various diagnostic and therapeutic agents for prostate cancer using bombesin (BBN) derivatives, but astatine-211 (At-211)-labeled BBN derivatives have yet to be studied. This study presented a preliminary evaluation of At-211- labeled BBN derivative. Several nonradioactive iodine-introduced BBN derivatives (IB-BBNs) with different linkers were synthesized and their binding affinities measured. Because IB-3 exhibited a comparable affinity to native BBN, [At-211]AB-3 was synthesized and the radiochemical yields of [At-211] AB-3 was 28.2 +/- 2.4%, with a radiochemical purity of >90%. The stability studies and cell internalization/externalization experiments were performed. [At-211]AB-3 was taken up by cells and internalized; however, radioactivity effluxed from cells over time. In addition, the biodistribution of [At-211]AB-3, with and without excess amounts of BBN, were evaluated in PC-3 tumor-bearing mice. Despite poor stability in murine plasma, [At-211]AB-3 accumulated in tumor tissue (4.05 +/- 0.73%ID/g) in PC-3 tumor-bearing mice, which was inhibited by excess native BBN (2.56 +/- 0.24%ID/g). Accumulated radioactivity in various organs is probably due to free At-211. Peptide degradation in murine plasma and radioactivity efflux from cells are areas of improvement. The development of At-211-labeled BBN derivatives requires modifying the BBN sequence and preventing deastatination.
• Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using ²¹¹At-Containing Targeted α-Particle Therapy Agent Which Promotes Endogenous Antitumor Immune Response
  作者：Shanshan Qin、Yuanyou Yang、Jiajia Zhang、Yuzhen Yin、Weihao Liu、Han Zhang、Xin Fan、Mengdie Yang、Fei Yu

  DOI：10.1021/acs.molpharmaceut.3c00427

  日期：2023.11.6